Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-β and fibroblast growth factor

Cancer

Volumn 97, Issue 7, 2003, Pages 1609-1615

  Zuetenhorst, Johanna M ^a   Bonfrer, Johannes M G M ^a   Korse, Catharina M ^a   Bakker, Rob ^b   Van Tinteren, Harm ^a   Taal, Babs G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

5 hydroxyindoleacetic acid (5 HIAA); Atrial natriuretic peptide (ANP); Carcinoid heart disease (CHD); Fibrosis; Serotonin

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 5 HYDROXYINDOLEACETIC ACID; ATRIAL NATRIURETIC FACTOR; FIBROBLAST GROWTH FACTOR; SEROTONIN; SOMATOSTATIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BLOOD LEVEL; CARCINOID SYNDROME; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNORADIOMETRIC ASSAY; LIVER METASTASIS; MALE; PRIORITY JOURNAL; SURVIVAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY; URINE LEVEL;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; CARCINOID HEART DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037378532     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11226     Document Type: Article

References (22)

1. Tornebrandt K, Eskilsson J, Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol. 1986;9:13-19.
2. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77:264-269.
3. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
4. Westberg G, Wangberg B, Ahlman H, Bergh CH, Beckman-Suurkula M, Caidahl K. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88:865-872.
5. Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1985;79:339-354.
6. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865.
7. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993;142:71-78.
8. Beauchamp RD, Coffey RJ Jr., Lyons RM, Perkett EA, Townsend CM Jr., Moses HL. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res. 1991;51:5253-5260.
9. Li CM, Khosla J, Hoyle P, Sannes PL. Transforming growth factor-beta(1) modifies fibroblast growth factor-2 production in type II cells. Chest. 2001;120:60S-61S.
10. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001;47:265-277.
11. Cappellin E, Gatti R, Spinella P, et al. Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta. 2001;310:49-52.
12. Lundin L, Oberg K, Landelius J, Hansson HE, Wilander E, Theodorsson E. Plasma atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol. 1989;63:969-972.
13. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425:547-560.
14. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829-1838.
15. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
16. Wee CC, Phillips RS, Aurigemma G, et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 1998;129:870-874.
17. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996;5:235-237.
18. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188-1196.
19. Strutz F, Zeisberg M, Renziehausen A, et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int. 2001;59:579-592.
20. Kadono T, Kikuchi K, Kubo M, Fujimoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol. 1996;35:392-397.
21. La Rosa S, Chiaravalli AM, Capella C, Uccella S, Sessa F. Immunohistochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. Virchows Arch. 1997;430:117-124.
22. Oppenheim JJ, Feldmann M. Cytokine reference, vol. 1. London: Academic Press, 2001.